刚才看到朋友发给我的Seres的消息： Seres Therapeutics Inc. shares were down 56% to $9.27 after the company said topline results from its Phase 2b study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis didn't meet its primary endpoint of improving clinical remission rates compared with placebo.Seres的药物SER-287在针对溃疡性结肠炎的II期实验结果不理想，导致股价暴跌，目前的价格为8.99美元，市值8.24亿美元。也同时牵连了隔壁的Finch公司，导致后者的股价也跌去一大截，目前的股价13.22美元，市值6.27亿美元。 从目前的情况来看，肠道微生态活菌药物这条路不好走，奋战在这条路上的朋友还需要加油，道路是曲折的，前途是光明的。
